T cell therapies.

S. Gottschalk; C. M. Bollard; K. C. Straathof; C. U. Louis; B. Savoldo; G. Dotti; Malcolm Brenner; Helen Heslop; C. M. Rooney

T cell therapies.

S. Gottschalk, C. M. Bollard, K. C. Straathof, C. U. Louis, B. Savoldo, G. Dotti, Malcolm Brenner, Helen Heslop, C. M. Rooney

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

T cell therapies are increasingly used for the treatment of malignancies and viral-associated diseases. Initial studies focused on the use of unmanipulated T cell populations after allogeneic stem cell transplantation. More recently, the use of antigen-specific T cells has been explored. This chapter reviews the clinical experience with polyclonal Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) for the treatment of EBV-associated malignancies. Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens.

Original language	English (US)
Pages (from-to)	69-82
Number of pages	14
Journal	Ernst Schering Foundation symposium proceedings
Volume	4
State	Published - 2006

ASJC Scopus subject areas

General Medicine

Cite this

@article{71ba4218b41144c48556751490758d73,

title = "T cell therapies.",

abstract = "T cell therapies are increasingly used for the treatment of malignancies and viral-associated diseases. Initial studies focused on the use of unmanipulated T cell populations after allogeneic stem cell transplantation. More recently, the use of antigen-specific T cells has been explored. This chapter reviews the clinical experience with polyclonal Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) for the treatment of EBV-associated malignancies. Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens.",

author = "S. Gottschalk and Bollard, \{C. M.\} and Straathof, \{K. C.\} and Louis, \{C. U.\} and B. Savoldo and G. Dotti and Malcolm Brenner and Helen Heslop and Rooney, \{C. M.\}",

note = "Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "2006",

language = "English (US)",

volume = "4",

pages = "69--82",

journal = "Ernst Schering Foundation symposium proceedings",

}

TY - JOUR

T1 - T cell therapies.

AU - Gottschalk, S.

AU - Bollard, C. M.

AU - Straathof, K. C.

AU - Louis, C. U.

AU - Savoldo, B.

AU - Dotti, G.

AU - Brenner, Malcolm

AU - Heslop, Helen

AU - Rooney, C. M.

N1 - Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

PY - 2006

Y1 - 2006

N2 - T cell therapies are increasingly used for the treatment of malignancies and viral-associated diseases. Initial studies focused on the use of unmanipulated T cell populations after allogeneic stem cell transplantation. More recently, the use of antigen-specific T cells has been explored. This chapter reviews the clinical experience with polyclonal Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) for the treatment of EBV-associated malignancies. Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens.

AB - T cell therapies are increasingly used for the treatment of malignancies and viral-associated diseases. Initial studies focused on the use of unmanipulated T cell populations after allogeneic stem cell transplantation. More recently, the use of antigen-specific T cells has been explored. This chapter reviews the clinical experience with polyclonal Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) for the treatment of EBV-associated malignancies. Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens.

UR - https://www.scopus.com/pages/publications/34548760252

UR - https://www.scopus.com/inward/citedby.url?scp=34548760252&partnerID=8YFLogxK

M3 - Review article

C2 - 17824182

AN - SCOPUS:34548760252

VL - 4

SP - 69

EP - 82

JO - Ernst Schering Foundation symposium proceedings

JF - Ernst Schering Foundation symposium proceedings

ER -

T cell therapies.

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this